Pure Global
NCT06357520

A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants

An Open-label, Fixed Sequence Study in Healthy Participants to Assess the Pharmacokinetics of Baxdrostat When Administered Alone and in Combination With Itraconazole
AstraZeneca·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
Baxdrostat
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
AstraZeneca
Location
Brooklyn, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Apr 16, 2024
End date
Jun 06, 2024
Enrollment
14 participants
Primary outcome

Area Under Plasma Concentration-Time Curve From Time Zero To Infinity (AUCinf),Maximum Observed Plasma Drug Concentration (Cmax)

Summary

The main purpose of this study is to assess the effect of itraconazole on the pharmacokinetic
 (PK) of baxdrostat.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06357520
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06357520 through Pure Global AI's free database. This Phase 1 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Healthy Participants. Target enrollment is 14 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.